Who ChondroFiller is actually right for

ChondroFiller is not a universal alternative to hip replacement — but for a specific group of patients it may meaningfully extend the working life of the hip joint before surgery becomes necessary.

The clearest candidates are those with a focal, contained cartilage defect affecting the hip joint, where the surrounding cartilage and bone remain relatively intact. These are typically patients with early-to-moderate joint wear: active enough to benefit from preservation, and still carrying enough viable tissue for the scaffold to work with. Anterosuperior acetabular lesions — often linked to femoroacetabular impingement — are among the defect patterns that have been treated with injectable collagen scaffold approaches.

Kellgren-Lawrence grading provides a useful reference point, but it does not determine eligibility on its own. Clinically, the distribution and containment of damage matters as much as the overall grade. Notably, the clinic states that a 'bone on bone' finding on imaging does not automatically exclude a patient from the injection pathway — a specialist hip assessment is needed to establish whether the defect pattern is suitable.

Certain conditions do rule the treatment out. Active joint infection, systemic inflammatory arthritis such as rheumatoid disease, immunosuppression, and poorly controlled diabetes are absolute contraindications.

Patients currently on an NHS waiting list for hip replacement — where the average wait sits at roughly 27 weeks — often represent the most relevant group: they have a defined clinical window and a clear reason to consider whether a joint-preserving option might delay or avoid surgery altogether.

Only a consultant hip assessment, supported by current imaging, can confirm whether ChondroFiller is appropriate for an individual patient.

What ChondroFiller is and how it works in the hip

Manufactured by meidrix biomedicals GmbH in Esslingen, Germany — using technology developed at the Fraunhofer Institute IGB in Stuttgart — ChondroFiller® (also marketed as Liquid Cartilage™) is a CE-marked Class III medical device. At its core it is an acellular injectable scaffold made from purified Type I collagen: the same structural protein that forms the basis of healthy cartilage.

Delivery is straightforward by the standards of hip treatment. Under ultrasound guidance, in an outpatient clinic setting and without a general anaesthetic or any incision, the collagen solution is injected directly into the hip joint. There is no theatre admission, no surgical wound, and no requirement to empty or dry the joint beforehand. Once inside the joint space, the liquid gels within approximately three to five minutes at body temperature, forming a stable three-dimensional matrix over the worn articular surface.

What follows is a biological rather than mechanical process. The scaffold is acellular — it contains no donor cells — but it acts as a chemotactic signal, drawing the patient's own progenitor cells in from the surrounding synovium and subchondral bone. Those cells migrate into the collagen matrix, mature into chondrocytes, and begin synthesising new cartilage matrix. This mechanism is referred to as acellular matrix-induced chondrogenesis: the scaffold does not deliver ready-made tissue, but rather supports the body's own repair processes by providing the structural environment in which those processes can occur.

As new matrix develops, the collagen scaffold biodegrades progressively. By 12 to 24 months it has been fully resorbed and replaced by the patient's own tissue. Throughout that period the primary goals are pain relief and mechanical protection of the hip joint surface.

How ChondroFiller compares with other hip injections

Not all hip injections share the same mechanism — and those differences matter when weighing options at different stages of joint deterioration.

Hyaluronic acid (HA) is a viscosupplement: it adds lubrication to the joint but does not repair or rebuild cartilage. Guideline support is inconsistent — OARSI offers conditional backing while AAOS and ACR are more sceptical — and any symptomatic benefit is generally short-lived.

Arthrosamid (polyacrylamide hydrogel) is a permanent, non-biodegradable cushion injected into the synovial tissue. It provides mechanical support but carries no regenerative function and remains in the joint indefinitely. The distinction from ChondroFiller is fundamental: Arthrosamid cushions; ChondroFiller scaffolds, recruits the patient's own cells, and biodegrades as new tissue matures.

Corticosteroids have a legitimate short-term role — reducing an acute inflammatory flare or managing pain ahead of another procedure. They are not a long-term strategy. A 2025 PROSPERO-registered meta-analysis (CRD42024526221) found no statistically significant WOMAC pain improvement for corticosteroid over placebo in hip OA, and the McAlindon 2017 JAMA trial documented progressive cartilage volume loss with repeated triamcinolone injections.

ChondroFiller sits above HA and Arthrosamid in regenerative intent — it is the only option in this comparison designed to initiate active biological repair via an acellular scaffold.

Lincolnshire Hip also offers PRP, mFAT, and BMAC for appropriate patients, each working through a distinct mechanism. PRP concentrates growth factors from the patient's own blood and may suit earlier-stage degeneration where inflammation is the primary driver. mFAT uses adipose-derived cells harvested from the patient to provide biologic support to the joint environment. BMAC concentrates marrow-derived progenitor cells and is generally considered in early osteoarthritis where biologic stimulation rather than structural scaffolding is the clinical aim. None of these options is interchangeable with the others; a specialist assessment is needed to match the mechanism to the individual joint picture.

What the evidence shows — and where the gaps are

The most clinically meaningful outcome figure from the manufacturer's April 2025 Clinical Evaluation Report (CER) is an approximate 30-point improvement in the modified Harris Hip Score (mHHS) in hip patients — a change considered clinically significant by established orthopaedic benchmarks. A parallel 30-point IKDC improvement is reported across knee patients in the same dataset. MOCART scores (a cartilage-specific MRI measure) ranged from 70 to 87, indicating consistent scaffold integration and tissue fill, and the product complaint rate across the full CER dataset is approximately 0.06%, supporting a favourable safety profile for a Class III medical device.

The evidence gap deserves plain acknowledgement: there is no published, hip-specific randomised controlled trial for ChondroFiller®. Much of the controlled outcome data originates from knee studies. Hip applicability is supported by the product's CE-mark scope covering the hip joint, by the manufacturer's hip-patient outcome data in the CER, by its deployment in the hip by Professor Paul Lee, and by the biological plausibility of acellular matrix-induced chondrogenesis in any synovial joint — but this is analogous rather than directly proven at RCT level. Long-term data beyond two years are still maturing across all joints.

For the question of whether biological cartilage repair in the hip is achievable at all, a 2025 histological case report offers useful proof-of-concept. A 46-year-old woman with hip OA received a single intra-articular autologous mesenchymal stem cell injection; at 18 months, histological analysis of the retrieved tissue confirmed hyaline-like cartilage in previously degenerated regions. This is not ChondroFiller® evidence — the mechanism is different — but it demonstrates that the hip joint can respond to biological intervention with cartilage regeneration, which underpins the broader clinical rationale.

By contrast, the evidence against routine corticosteroid use in hip OA continues to accumulate. A 2025 PROSPERO-registered meta-analysis (CRD42024526221) found no statistically significant WOMAC pain improvement over placebo, and a separate retrospective study of 120 injected hip patients found 20.8% developed rapidly destructive arthrosis and 22.5% progressed to total hip arthroplasty. These figures do not constitute a direct head-to-head comparison with ChondroFiller, but they are relevant context when patients are weighing which non-surgical pathway carries the most risk of inadvertently accelerating joint deterioration.

The NHS waiting-list window and why timing matters

Within the NHS hip replacement pathway, the period between referral and surgery is rarely clinically neutral. Cartilage continues to wear, adaptive muscle patterns entrench, and the joint environment a surgeon will eventually work with changes incrementally.

A published clinical case account documents the compounding effect of a hip left to deteriorate without active management: by the time replacement became unavoidable, the operating team encountered distorted anatomy, accumulated scar tissue, and a procedure substantially longer and more complex than a routine replacement — with recovery measured accordingly. The account illustrates a broader clinical principle: earlier intervention, while joint architecture is still workable, may protect the quality of an eventual surgical outcome as well as function in the interim.

ChondroFiller is best positioned within this window as a proactive choice rather than a last resort after every other option has been exhausted. Its 12–24 month biological timeline aligns meaningfully with the NHS waiting period: a patient who proceeds with the injection at an appropriate stage may achieve measurable improvement in symptoms and joint function before surgery becomes due. Choosing it does not foreclose hip replacement — it simply keeps better options available for longer.

For Lincolnshire patients who want to act within this window, a specialist assessment with Professor Paul Lee at Grantham or Sleaford requires no GP referral, which removes one routine source of delay at the earliest decision point.

Getting assessed at Lincolnshire Hip

Professor Paul Y.F. Lee was the first clinician in the UK to offer ChondroFiller® as an injection, and provides the treatment locally through Lincolnshire Hip at Grantham and Sleaford, alongside PRP and Arthrosamid, as part of a non-surgical hip injection pathway.

A specialist consultation is priced at £250 with no GP referral needed to book. At that appointment, Professor Lee will assess Kellgren-Lawrence grade, defect type, symptom profile, and whether the patient meets the eligibility criteria described above — including the important question of whether the joint still has workable cartilage architecture. ChondroFiller is priced from £3,000 for the injection itself. It is a private treatment; NICE has not approved it for routine NHS funding.

For a patient currently on an NHS waiting list, the honest summary is this: the evidence base is promising but still maturing, the biological mechanism is sound, and the window in which joint-preserving intervention is most likely to be effective is finite. Acting before the joint deteriorates further — rather than waiting until surgery is the only remaining option — is the decision that this treatment is designed to support.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] Cartilage Repair and Symptom Relief After Autologous Microfragmented Adipose-Derived MSC Therapy in Hip Osteoarthritis: A Case Report with Histological Correlation. (2025). https://doi.org/10.2174/011574888X388459250915055552 https://doi.org/10.2174/011574888X388459250915055552
2. [2] Pain management of hip osteoarthritis with corticosteroids vs injection therapies: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s12891-025-08666-0 https://doi.org/10.1186/s12891-025-08666-0
3. [3] Frequency of Destructive Hip Disease Post Intra-Articular Corticosteroid Hip Injection. (2022). https://doi.org/10.53350/pjmhs22163344 https://doi.org/10.53350/pjmhs22163344